



OPEN ACCESS

EDITED AND REVIEWED BY
José A. G. Agúndez,
University of Extremadura, Spain

*CORRESPONDENCE

Simran Maggo,
✉ simran.maggo@su.edu
Xiaowu Gai,
✉ xgai@mcw.edu

RECEIVED 02 June 2025

ACCEPTED 25 June 2025

PUBLISHED 08 July 2025

CITATION

Maggo S, Pan Y, Ostrow D, Nguyen JQ,
Biegel JA, Deardorff MA and Gai X (2025)
Correction: Clinical impact of
pharmacogenomics in pediatric care: insights
extracted from clinical exome sequencing.
Front. Genet. 16:1639666.
doi: 10.3389/fgene.2025.1639666

COPYRIGHT

© 2025 Maggo, Pan, Ostrow, Nguyen, Biegel,
Deardorff and Gai. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other forums is
permitted, provided the original author(s) and
the copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Correction: Clinical impact of pharmacogenomics in pediatric care: insights extracted from clinical exome sequencing

Simran Maggo^{1,2*}, Yachen Pan², Dejerianne Ostrow²,
Jenny Q. Nguyen³, Jaclyn A. Biegel^{2,4}, Matthew A. Deardorff^{3,4}
and Xiaowu Gai^{2,4,5,6*}

¹Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, United States, ²Center for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, United States, ³Personalized Care Program, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, United States, ⁴Department of Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, ⁵Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, United States, ⁶Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, United States

KEYWORDS

pharmacogenomic (PGx) research, pharmacogenetic testing, bioinformatic analyses, admixed american pharmacogenomics, pharmacogenomics data

A Correction on

[Clinical impact of pharmacogenomics in pediatric care: insights extracted from clinical exome sequencing](#)

by Maggo S, Pan Y, Ostrow D, Nguyen JQ, Biegel JA, Deardorff MA and Gai X (2025). *Front. Genet.* 16:1574325. doi: 10.3389/fgene.2025.1574325

In the published article, there was an error in [Table 1](#) as published. Table one, included two instances of SLCO1B1. The first instance should be CYP2B6. The corrected [Table 1](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 1 Phenotype frequency (%) comparison of the Whole Exome Sequencing cohort (CES) against data published on the PharmGKB (PGKB) website and a recent publication (LIT) (Tremmel et al., 2023). For population comparisons, AMR (Admixed American) from CES was compared against LAT (Latino) from PGKB due to differences in biogeographical classifications. Blank values for, PGKB, or LIT indicate values not available at the time of publication.

CYP2B6	AFR			AMR			EAS			EUR			SAS		
	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT
Normal Metabolizer	22	33.4	25.4	34.2	33.6	35.4	54.5	48.6	51.2	48.2	43	51.2	34.2	42.2	30.9
Intermediate Metabolizer	54.9	46.6	47.7	42.1	42.2	43.5	26.9	32.6	33.1	37.1	38	35.1	42.1	36.5	45.4
Poor Metabolizer	20.9	15.7	21.5	13.2	9.5	16.4	7.1	4.4	5.2	6.2	7.4	5.8	13.2	6	15.1
Rapid Metabolizer	1.1	1.2	2.7	5.3	12.3	1.4	10.3	11.7	9.3	5.2	5.4	4.8	5.3	12.9	6.5
Ultrarapid Metabolizer	0	0	0	2.6	1.1	0	0	0.7	0.4	0.2	0.2	0.4	2.6	1	0.0
Indeterminate	1.1	3.1	2.2	2.6	1.4	3.1	1.3	2	0.8	3.1	6.1	2.8	2.6	1.5	2.0
CYP2D6	AFR			AMR			EAS			EUR			SAS		
	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT
Normal Metabolizer (1.25 ≤ x ≤ 2.25)	62.6	31.4	50.1	64.3	54.6	65.1	62.8	52.1	52.4	49.6	48.2	48.4	65.8	57.8	59.7
Intermediate Metabolizer (0 < x < 1.25)	22	59.7	36.2	25.5	34.2	24.2	28.8	40	44.6	36.8	39.3	38.4	23.7	28.4	25.4
Poor Metabolizer (0)	3.3	2.3	2.1	3.6	3.1	3.5	1.9	0.8	0.0	7.1	6.5	6.2	2.6	2.4	2.9
Ultrarapid Metabolizer (>2.25)	0	2.6	5.1	0.2	3.8	3.2	0	0.8	1.0	0	2.3	3.0	0	1.5	1.2
Indeterminate	12.1		6.5	6.3		4.0	6.4		2.0	6.4		4.0	7.9		10.8
ABCG2	AFR			AMR			EAS			EUR			SAS		
	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT
Normal Function	92.3	93.1	98.2	61.8	60.2	79.3	50	48	72.0	81.7	80.4	89.0	86.8	82.2	81.4
Decreased Function	7.7	6.7	1.8	32.7	34.8	19.9	42.9	42.6	23.8	17.1	18.6	10.2	10.5	16.9	18.2
Poor Function	0	0.1	0.0	5.5	5	0.9	7.1	9.4	4.2	1.2	1.1	0.8	2.6	0.9	0.4
CYP2C9	AFR			AMR			EAS			EUR			SAS		
	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT
Normal Metabolizer	79.1	75.9	78.5	76.6	74.3	72.9	89.1	83.8	91.7	62	62.8	63.1	60.5	59.6	68.7
Intermediate Metabolizer	20.9	23.6	21.2	23.1	24.6	26.2	9.6	15.2	8.1	35.6	34.5	34.7	36.8	36.2	27.2
Poor Metabolizer	0	0.5	0.3	0.2	1	0.9	0	0.6	0.2	2.1	2.6	2.2	2.6	3.8	2.7
Indeterminate	0	0	0.0	0.2	0.1	0.0	1.3	0.5	0.0	0.2	0.1	0.0	0	0.4	1.4
SLCO1B1	AFR			AMR			EAS			EUR			SAS		
	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT
Normal Function	69.2	98	51.7	76.7		50.4	70.5	75.7	72.2	63.2	65.6	39.2	89.5	86.5	72.6
Decreased Function	13.2	2	1.4	18.7		19.9	26.3	21.8	19.8	25.7	28.3	20.1	7.9	13	7.0
Possible Decreased Function	1.1	0	5.1	0.6		0.0	0.6	0.1	0.0	0.7	0	0.0	0	0	0.0

(Continued on following page)

TABLE 1 (Continued) Phenotype frequency (%) comparison of the Whole Exome Sequencing cohort (CES) against data published on the PharmGKB (PGKB) website and a recent publication (LIT) (Tremmel et al., 2023). For population comparisons, AMR (Admixed American) from CES was compared against LAT (Latino) from PGKB due to differences in biogeographical classifications. Blank values for, PGKB, or LIT indicate values not available at the time of publication.

SLCO1B1	AFR			AMR			EAS			EUR			SAS		
	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT	CES	PGKB	LIT
Poor Function	0	0	0.2	0.8		1.7	1.9	1.6	2.0	3.8	2.9	2.0	0	0.5	0.4
Increased Function	2.2	0		0.7			0	0		3.3	3		2.6	0	
Indeterminate	14.3	0	33.3	2.6		13.8	0.6	0.8	5.4	3.3	0.1	18.7	0	0.1	8.4
HLA - Allele	AFR			AMR			EAS			EUR			SAS		
	CES	PGKB		CES	PGKB		CES	PGKB		CES	PGKB		CES	PGKB	
HLA-A*31:01	0	0.99		1.63	4.52		0.96	3.45		0.59	2.64		0	3.3	
HLA-B*15:02	0.55	0.1		0	0.03		6.73	4.56		0	0.01		0	2.59	
HLA-B*57:01	0	0.61		0.56	1.39		0.32	0.98		3.09	3.6		5.26	6.81	
HLA-B*58:01	2.75	3.82		1.07	1.35		3.85	6.04		0.48	0.77		3.95	4.19	